Skip to main content
WAVERLEY PHARMA INC. logo

WAVERLEY PHARMA INC. — Investor Relations & Filings

Ticker · WAVE ISIN · CA94357L1058 LEI · 254900VT8CXPPV1G5Q51 TSXV Manufacturing
Open in API
Filings indexed 110 across all filing types
Latest filing 2025-04-29 Audit Report / Informat…
Country CA Canada
Listing TSXV WAVE

About WAVERLEY PHARMA INC.

https://www.waverleypharma.com/

Waverley Pharma Inc. is a specialty biopharmaceutical company engaged in the research, development, and commercialization of safe, effective, and affordable therapeutics. The company primarily focuses on oncology, developing treatments such as poly ADP-ribose polymerase-1 (PARP-1) inhibitors for cancer. Waverley Pharma commercializes its pharmaceutical products in markets including the United Kingdom, evidenced by successful tenders for drugs like Capecitabine with NHS Scotland. Furthermore, the company operates a retail pharmacy in the United States, integrating pharmaceutical innovation with direct patient service operations.

Recent filings

Filing Released Lang Actions
Audited annual financial statements – English.pdf
Audit Report / Information Classification · 98% confidence The document is the Independent Auditor’s Report and the audited consolidated financial statements for the year ended December 31, 2024, detailing the audit opinion, key audit matters, and full financial statements. This matches a standalone audit report rather than an entire annual report or earnings release. Therefore, it is classified as an Audit Report / Information (AR). FY 2024
2025-04-29 English
Notice of the meeting and record date - English.pdf
Regulatory Filings Classification · 80% confidence The document is a formal notice to Canadian Securities Regulatory Authorities from the company’s transfer agent, detailing dates and procedures for the upcoming Annual and Special Meeting, proxy distribution, and voting security details. It does not contain proxy materials themselves (so it is not a PSI) nor is it an actual report (10-K, IR, etc.), but rather a regulatory announcement of meeting particulars. This fits the fallback category for miscellaneous regulatory filings.
2025-04-10 English
News release - English.pdf
M&A Activity Classification · 95% confidence The document is a press release announcing that Waverley Pharma has entered into a definitive agreement to acquire 100% of the membership interests of C&R Pharmacy. It details the acquisition terms, the strategic rationale, and includes forward-looking statements typical of acquisition announcements. There are no financial statements, quarterly or annual results, or regulatory filings referenced as attached or published. The content focuses on a merger and acquisition activity, specifically an acquisition transaction. Therefore, the document fits the category of M&A Activity (TAR). The document length is sufficient and contains substantive information about the transaction, not just an announcement of a report or a certification.
2024-09-24 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification by the CFO of Waverley Pharma Inc. regarding the interim financial report and interim MD&A for the period ended June 30, 2024. It is a Form 52-109FV2 certification specific to venture issuers, confirming the review and fair presentation of the interim filings. The document does not contain actual financial data or the interim report itself but is an officer certification related to the interim filings. According to the Certification Rule, such certifications should be classified as Regulatory Filings (RNS) rather than the interim report (IR) itself.
2024-08-26 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a FORM 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate signed by the CEO. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended June 30, 2024. The document is primarily an officer certification letter and does not contain actual financial data or the interim report itself. According to the CERTIFICATION RULE, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report (IR). The document length is short (3004 characters) and it is a certification, not the report itself.
2024-08-26 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Management Discussion and Analysis' (MD&A) for Waverley Pharma Inc. for the three and six months ended June 30, 2024. It contains detailed financial performance analysis, discussion of operational results, forward-looking statements, and references to condensed consolidated interim financial statements. The period covered is a quarter and half-year, and the document includes substantive financial data and analysis. The MD&A is a management report explaining financial results and business trends for an interim period, which fits the definition of an Interim / Quarterly Report (IR). The document is not a brief announcement, not a full annual report, nor a regulatory filing or certification. Therefore, the correct classification is Interim / Quarterly Report (IR) with high confidence.
2024-08-26 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.